A Cross-Sectional Study of Human Immunodeficiency Virus-Associated Neurocognitive Deficit in Central India

Dr. Saptarshi Maitra 1, Mrinalini Motlag 1

1. Internal Medicine, Indira Gandhi Government Medical College, Nagpur, IND

Corresponding author: Dr. Saptarshi Maitra, dr.saptarshimaitra@hotmail.com

Abstract

Background

With the advent of modern era of combination antiretroviral therapy (cART) and increased longevity of people living with human immunodeficiency virus (PLHIV), human immunodeficiency virus-associated neurocognitive disorder (HAND) is commonly observed. This study explores the prevalence of HAND and the demographic and treatment variables in people with HAND, in Central India.

Research methodology

PLHIV on cART visiting HIV clinic underwent screening for substance abuse using CAGE-AID, and depression using PHQ-2 followed by PHQ-9. The screening rules out overt conditions which might interfere with cognitive abilities of the individual and thereby act as confounding factor. Thus, a sample population of 96 was obtained, on whom International HIV Dementia Scale (IHDS) was applied to screen for dementia. Out of 96, 16 individuals detected to suffer from HAND. Quality of Life was assessed by Patient’s Assessment of Own Functioning Inventory (PAOFI).

Results

Prevalence of HAND was estimated to be 16/96 (16.66%). It was more common amongst unmarried individuals (p < 0.001) and lower educational status (p < 0.01) among social variables; while shorter duration of ART (<3 years) (p < 0.01) and lower CD4 nadir (<200 cell/mm^3; p<0.01) showed significant correlation among clinical variables. PAOFI revealed significant association between HAND and quality of life (p-value < 0.01, CI = 95%). Modified Mental State Examination (3MS), which determines cognitive ability in various domains based on tasks, was mostly affected for - similarities and read and obey (for 43.75% population).

Conclusion

Social and clinical variables play a significant role in development of HAND. Routine screening for HAND in PLHIV will help in early identification and management of the disease. The quality of life for those suffering from the burden of HIV and HAND can be significantly improved if approached and treated early in the course of the disease.

Introduction

The pandemic of the human immunodeficiency virus (HIV), first recognised in 1981, has engulfed the entire planet in less than four decades. The number of infected individuals was as high as 37.9 million, by the end of 2018, according to The Joint United Nations Programme on HIV and AIDS (UNAIDS) [1]. The majority (95%) of these people living with HIV (PLHIV) reside in low- and middle-income categories [1]. With the advent of the era of modern medicine and combination antiretroviral therapy (cART), we see a constant decline in morbidity and mortality. With increasing chronicity, novel manifestations of the disease are starting to unravel themselves. One of the major complications of HIV observed in chronic cases is HIV-associated neurocognitive disorder (HAND). HAND includes a spectrum of neurocognitive changes, involving personality, motor, and cognitive changes. It ranges from asymptomatic neurocognitive impairment (ANI) - where the patient has no deficits on neurocognitive tests or with activities of daily living (ADL) or instrumental activity of daily living (IADL), to HIV-associated dementia (HAD) which is a severe form of HAND, causing significant difficulties in performing tasks of daily living [2]. The cognitive decline caused by HIV, however mild, when coupled with age and other co-morbidities causes increased difficulty to independent living. Therefore, the early screening and management of this disorder provide an opportunity to prevent such a fate. This study aims at shedding light on the following topics: (i) to estimate the
Materials And Methods

This cross-sectional study was carried out in Central India after the approval of the Institutional and Ethics Committee of Indira Gandhi Government Medical College and Mayo Hospital, Nagpur (IRB Approval Number - IGGMC/Pharmacology/IEC/68/2016). The inclusion criteria used for the sample population were - previously diagnosed PLHIV on cART for at least one year, age more than 18 years, International HIV Dementia Scale (IHDS) < 10, and willingness to provide informed consent.

While the exclusion criteria for the sample population were - current alcohol/drug abuse, systemic hypertension, diabetes mellitus, stroke, chronic kidney disease (CKD), chronic liver disease (CLD), and any psychiatric illness.

Participants were screened in accordance with the exclusion criteria and risk factors identified by Saylor et al. [3]. CAGE Adapted to Include Drugs (CAGE-AID) Questionnaire was used to eliminate those with alcohol/drug abuse [4,5]. Patient Health Questionnaire-2 (PHQ-2) was used for undiagnosed depression. Those who screened positive were further evaluated by PHQ-9. This tool allows for the screening, diagnosing, monitoring, and measuring of the severity of depression.

Ninety-six HIV cases were found fit to participate in the research study. The case record forms were duly filled. Individuals were classified on the basis of them having been educated up to the 12th standard or not [6]. IHDS, a four-item set of tests was completed by a clinician, include memory task, finger tapping, a sequential motor task (Luria Sequence), and recall [7]. The choice of using IHDS over Mini-Mental State Examination (MMSE) is substantiated by several studies including the one done by Oshinaike et al. [8].

Modified Mini-Mental State Examination was used to identify cognitive impairment in various domains. The cognitive domain examined were orientation, registration, mental reversal, first recall, temporal orientation, spatial orientation, naming, four-legged animals, similarities, repetition, read and obey, writing, copying two Pentagons, three-staged command,s and second recall.

The PAOFI was administered to identify the impairment in the daily activities of the participants. Frascati criteria require >2SD affection in at least two cognitive domains in 3MS to qualify as HAND [2].

Results

Distribution of demographic variables in the study population

The population was stratified on the basis of age and gender to understand the diversity. Table 1 shows the distribution of different participants based on age and gender. The highest number of participants belong to the age group of 41-50 years followed by 51-60 years.

| Age (years) | Males | Females | Total |
|-------------|-------|---------|-------|
| 20–30       | 8     | 2       | 10    |
| 31–40       | 10    | 5       | 15    |
| 41–50       | 17    | 19      | 36    |
| 51–60       | 16    | 11      | 27    |
| >61         | 3     | 5       | 8     |

**TABLE 1: Age gender distribution of PLHIV on cART (n = 96)**
cART: combined antiretroviral therapy. PLHIV: people living with human immunodeficiency virus.
than 12th standard (males - 35, females - 26). The discrepancies in the other variables are significantly less apparent.

| Marital status | Married | Unmarried |
|----------------|---------|-----------|
|                | Males   | Females   | Males | Females |
|                | 42      | 31        | 12    | 11      |

| Educational status | Educated > 12th std | Educated ≤12th std |
|--------------------|---------------------|--------------------|
|                    | Males | Females | Males | Females |
|                    | 19    | 16      | 35    | 26      |

| Caretaker | Present | Absent |
|-----------|---------|--------|
| Males     | 26      | 28     |
| Females   | 27      | 15     |

| Duration of cART | <3 years | ≥3 years |
|------------------|---------|---------|
| Males | Females | Males | Females |
| 30    | 27      | 24     | 15      |

| CD 4 count | <200 cells/mm³ | ≥200 cells/mm³ |
|------------|----------------|----------------|
| Males      | Females        | Males | Females |
| 15         | 16              | 39    | 26      |

### TABLE 2: Distribution of PLHIV on cART according to social variables

Std: standard, cART: combined anti-retroviral therapy, HAND: human immunodeficiency virus-associated neurocognitive deficit, CD 4: cluster of differentiation 4

Upon applying the Frascati principle, groups of individuals with and without HAND were formed. Most individuals being in the age group of 41-50 years, and having more male participants as shown in Table 3.

| Age (years) | Males | Females | Total |
|-------------|-------|---------|-------|
| 20–30       | 0     | 0       | 0     |
| 31–40       | 2     | 1       | 3     |
| 41–50       | 4     | 3       | 7     |
| 51–60       | 3     | 2       | 5     |
| >61         | 0     | 1       | 1     |
| Total       | 16    |         |       |

### TABLE 3: Distribution of cases of HAND in the study population

HAND: human immunodeficiency virus-associated neurocognitive deficit

Comparison of social variables in relation to HAND

From Table 4, we can infer that HAND is more common among unmarried participants and those who had completed education beyond high school. Using the Chi-squared table, marital status (p < 0.001) and education status (p < 0.003) turn out to be of significance. The frequency of HAND was considerably less in married participants as compared to unmarried counterparts. The discrepancy is significantly lesser when it comes to the presence of caretakers in the study population.
### TABLE 4: Distribution of individuals with HAND amongst various social groups

| Marital status | Married | | Unmarried | |
|---------------|---------|---|-----------|---|
| | Males | Females | Males | Females |
| | 1 | 2 | 9 | 4 |
| Educational status | | | | |
| | Educated >12th std | | Educated ≤12th std | |
| | Males | Females | Males | Females |
| | 3 | 1 | 7 | 5 |
| Caretaker | | | | |
| | Males | Females | Males | Females |
| | 5 | 4 | 5 | 2 |

Std: standard, HAND: human immunodeficiency virus-associated neurocognitive deficit

---

### Comparison of clinical variables in relation to HAND

Tables 5-6 illustrate the mean and the statistical significance of clinical variables. The tables infer a negative correlation between the presence of HAND and the duration of cART as well as CD4 nadir.

### TABLE 5: Mean of clinical variables in study groups with and without HAND

cART: combined anti-retroviral therapy, HAND: human immunodeficiency virus-associated neurocognitive deficit, PLHIV: people living with human immunodeficiency virus, CD4: cluster of differentiation 4

| Category | Chi-square value | dF value | P-value |
|----------|------------------|----------|---------|
| CD 4 count Nadir | 7.39 | 1 | 0.006 |
| Duration of cART | 7.08 | 1 | 0.007 |

### TABLE 6: Relationship of clinical variables (CD4 count nadir and duration of cART) with HAND

cART: combined anti-retroviral therapy, CD4: cluster of differentiation 4, HAND: human immunodeficiency virus-associated neurocognitive deficit

---

### Cognitive domain involvement in PLHIV with and without HAND using 3MS

Amongst the various domains assessed under the 3MS, we can see a greater number of participants with HAND performing poorly than those without. Out of the 15 domains tested in PLHIV with HAND (Figure 1), similarities and read and obey were maximally affected at 43.75%. This is followed by spatial orientation, writing, repetition, and second recall at 37.5%. Orientation and three-staged command were least affected at 12.5%. In PLHIV without HAND (Figure 2), writing was most affected at 26.2%, while orientation was least affected at 11.5%.

2021 Maitra et al. Cureus 13(10): e18776. DOI 10.7759/cureus.18776
Assessment of effect on daily activities in PLHIV with and without HAND using PAOFI

Table 7 below shows the difference in scores attained by participants with and without HAND on PAOFI. The overall Chi-square value of 12.09, p-value <0.00 for CI = 95%. The individual tests were found to have Chi-square values of 55.54 (Memory), 24.03 (Language and Communication), 45.22 (Motor), 75.23 (Sensory), and 39.30 (Higher function) arriving at a p-value of <0.01 with CI = 95%. Hence, the prediction of the test is
significant for the deficit in all domains, and HAND can be strongly suspected in a positive test.

| Domains tested (total score) | Mean score in PLHIV with HAND | Mean score in PLHIV without HAND |
|-----------------------------|-----------------------------|---------------------------------|
| Memory (60)                 | 23.58 ± 12.36               | 58.13 ± 4.09                    |
| Language and communication (54) | 21.29 ± 9.58               | 52.15 ± 4.15                    |
| Motor (12)                  | 4.64 ± 2.89                 | 11.67 ± 0.72                    |
| Sensory (18)                | 5.47 ± 3.44                 | 16.54 ± 2.53                    |
| Higher functions (54)       | 20.70 ± 11.10               | 51.87 ± 8.26                    |
| The total score of PAOFI (168) | 75.70 ± 19.65               | 190.37 ± 9.89                   |

**TABLE 7: Comparison of mean of scores of PAOFI in individuals with and without HAND**

HAND: human immunodeficiency virus-associated neurocognitive deficit, PLHIV: people living with human immunodeficiency virus, PAOFI: Patient’s Assessment of Own Functioning Inventory

**Discussion**

A cross-sectional study of 96 pre-diagnosed PLHIV on cART, satisfying the inclusion and exclusion criteria, were evaluated for HAND to study the association of social and clinical variables with the disease. The association of the social variables (Tables 1–4) namely age, marital status, educational status, caretaker, and clinical variables (Tables 5–6) namely duration of cART and CD4 count with HAND were studied. The cognitive domains involved in PLHIV and activities of daily living were assessed.

On applying the Frascati criteria to the study population, 16 participants (16.66%) were found to have HIV-associated neurocognitive deficits. The percentage of the affected population was similar to the CHARTER study at 22.7%; the study was done by Schouten et al. at 15–50% and Gisslén et al. at 15.9% [9-11].

From Table 1, we see that HAND was slightly higher amongst male participants (10), whereas it was noted in six female participants. This was not statistically significant. Kumar et al. have postulated that the disease load is high amongst males and they have proportionately greater utilisation of the health system [12].

From Tables 2–4, we observe that marital status and educational status have a significant negative association with HAND. Gender and the presence of caretakers held no such significant association. Support provided by spouse and family may have contributed to better cognition as married individuals performed better. Lower educational level is associated with neurocognitive impairment in a study done by Yusuf et al. in the Nigerian population [13]. We have hypothesised that the cause of the association of neurocognitive deficit with lower education could be poorer synaptic development. These synapses may then be more prone to damage by the viral particle.

In Tables 5–6, the duration of ART has been categorised between <3 and ≥3 years [9]. HAND was present in 12 participants who received ART for <3 years and in 4 who received it for ≥3 years. Lower CD4 nadir (<200 cell/mm$^3$) shows a higher number of cases at 11 while ≥200 CD4 cell/mm$^3$ is seen in five cases. The specific cut-off at 200 CD4 cell/mm$^3$ nadir was taken in accordance with the CHARTER study findings [9]. A significant negative correlation was noted between the duration of ART and CD4 nadir with HAND. Studies performed by Kumar et al. and Njamshi et al. identify a negative correlation between the duration of ART and CD4 nadir [12,14]. This negative association points towards the pathophysiology of the disease which suspects the transmission of viral protein across the blood-brain barrier causing damage to cortical tissue. The low CD4 nadir is used as an indirect marker for higher disease load. The higher disease load could be attributed to shorter duration cART or to the poorer compliance to medication due to absence of understanding owing to poor educational status.

On administration of Modified Mini State Examination to identify the pattern of affection of cognitive domains among HAND patients in the sample population, it is observed that there was a maximum reduction in similarities and read and obey at 43.75%. A study performed by Kumar et al. showed the maximum reduction in similarities at 48.3% of their sample population, while read and obey showed a reduction in only 24% of the population [12]. The minimum reduction, in this study, was seen in orientation and three-staged command at 12.5%. similar to the study conducted by Kumar et al., showing only 1.8% population showing a reduction in orientation and 0% population showing a reduction in three-staged command [12]. The above data are inferred from the data represented in Figures 1-2.
PAOFI provides information regarding the difficulty the patient experiences in day-to-day activities because of underlying cognitive deficit. The mean score of PLHIV with HAND was recorded at 75.70 ± 19.65, while those without HAND were 190.37 ± 9.89. The significant reduction of score attributes to the difficulty faced by patients in performing day-to-day activities. The above data are inferred from the data represented in Table 7.

**Limitations**

Further investigation and research in the cognitive domains normative data of Indian population with its vast discrepancies in educational and socioeconomic status. This is recommended amongst the high-risk population of lower socioeconomic class which form a substantial part of PLHIV in India. The clinic diagnosis of HAND if substantiated with biochemical and radiological investigations increase the probability of diagnosis, especially in patients with significant co-morbidities.

**Conclusions**

The study conducted reveals a higher prevalence of HIV-associated neurocognitive deficit in patients who were unmarried, received education for less than 12th standard, had a CD4 count <200 cell/mm$^3$, and were on cART for less than three years. Use of 3MS indicates maximum involvement in similarities and read and obey amongst all the other tests. PAOFI reveals significant deterioration of the ability to perform daily activities in patients of HAND. These tests, if used in screening HIV-positive patients, can be indicative of underlying cognitive impairment.

**Appendices**
CAGE-AID Questionnaire

The CAGE Adapted to Include Drugs (CAGE-AID) Questionnaire, used to screen for lifetime use of alcohol and drugs*.

*Drug use (illegal drug use and the use of prescription drug use other than what they are prescribed for).

**Informed consent**

☐ I have understand and willfully participate in the research by answering the following questions.

| Response          | Yes | No |
|-------------------|-----|----|
| Points scored     | +1  | -1 |

**C**: Have you ever felt that you ought to Cut down on your drinking or drug use?

**A**: Have people Annoyed you by criticizing your drinking or drug use?

**G**: Have you ever felt bad or Guilty about your drinking or drug use?

**E**: Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover (Eye opener)?

Final answer to be assessed for interpretation

**Interpretation**

One or more "yes" responses is regarded as a positive screening test, indication possible substance use and need for further evaluation.

Source: Brown RL, Rounsaville BJ, Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. 
Wu Med J. 1993;94:135-40.

Hoskins CH, Castellan NA, Dickson-Fuhrman K, Dunn G, Jaffe J, Jarvik L. Screening for drug and alcohol abuse among older adults using a modified version of the CAGE. Am J Addict. 2001;10:319-26.

The above Questionnaire is adapted from https://www.hiv.cw.edu/page/substance-use/cage-aid.

---

**FIGURE 3: CAGE-AID questionnaire**
| 3MS | MMS |
|-----|-----|
| DATE AND PLACE OF BIRTH | 0 1 2 3 |
| Date: year _______ | 0 1 2 |
| month __ day _____ | 0 2 3 |
| Place: town ___________ | 0 1 2 |
| state ________________ | 0 2 3 |
| REGISTRATION | 0 2 3 |
| (No. of presentations: | 0 2 3 |
| SHIRT, BROWN, HONESTY | 0 1 2 3 |
| (or: SOCKS, BLACK, | 0 2 3 |
| MODESTY) | 0 1 2 3 |
| (or: SOCKS, BLUE, CHARITY) | 0 2 3 |
| MENTAL REVERSAL | 0 2 3 |
| 5 to 1 | 0 1 2 3 4 5 |
| Accuracy | 0 1 2 3 4 5 |
| 1 or 2 errors/misses | 0 1 2 3 4 5 |
| DLSCW | 0 1 2 3 4 5 |
| FIRST RECALL | 0 1 2 3 4 5 |
| Spontaneous recall | 0 1 2 3 4 5 |
| After "Something to wear" | 0 1 2 3 4 5 |
| "SHOES, SHIRT, SOCKS" | 0 1 2 3 4 5 |
| Spontaneous recall | 0 1 2 3 4 5 |
| After "A color" | 0 1 2 3 4 5 |
| "BLUE, BLACK, BROWN" | 0 1 2 3 4 5 |
| Spontaneous recall | 0 1 2 3 4 5 |
| After "A good personal quality" | 0 1 2 3 4 5 |
| "HONESTY, CHARITY, MODESTY" | 0 1 2 3 4 5 |
| TEMPORAL ORIENTATION | 0 1 2 3 4 5 |
| Year | 0 1 2 3 4 5 |
| Accuracy | 0 1 2 3 4 5 |
| Missed by 1 year | 0 1 2 3 4 5 |
| Missed by 2-5 years | 0 1 2 3 4 5 |
| Season | 0 1 2 3 4 5 |
| Accuracy or within 1 month | 0 1 2 3 4 5 |
| Month | 0 1 2 3 4 5 |
| Accuracy or within 5 days | 0 1 2 3 4 5 |
| Missed by 1 month | 0 1 2 3 4 5 |
| Day of month | 0 1 2 3 4 5 |
| Accuracy | 0 1 2 3 4 5 |
| Missed by 1 or 2 days | 0 1 2 3 4 5 |
| Missed by 3-5 days | 0 1 2 3 4 5 |
| Day of week | 0 1 2 3 4 5 |
| Accuracy | 0 1 2 3 4 5 |
| SPATIAL ORIENTATION | 0 1 2 3 4 5 |
| State | 0 1 2 3 4 5 |
| County | 0 1 2 3 4 5 |
| City (town) | 0 1 2 3 4 5 |
| Hospital/office building/home? | 0 1 2 3 4 5 |

**FIGURE 4: Modified Mini-Mental State Examination form**

**The Modified Mini-Mental State (3MS)**

| 3MS | MMS |
|-----|-----|
| NAMING | 0 1 2 3 4 5 |
| (MMS: Pencil | 0 1 2 3 4 5 |
| Forehead ___ Chin ___ | 0 1 2 3 4 5 |
| Shoulder ___ Knuckle ___ | 0 1 2 3 4 5 |
| FOUR-LEGGED ANIMALS (50 seconds) | 0 1 2 3 4 5 |
| SENSATION | 0 1 2 3 4 5 |
| Arm-Leg | 0 1 2 3 4 5 |
| Body part, limb, etc | 0 1 2 3 4 5 |
| Less correct answer | 0 1 2 3 4 5 |
| Laughing-Crying | 0 1 2 3 4 5 |
| Rating: emotion | 0 1 2 3 4 5 |
| Other correct answer | 0 1 2 3 4 5 |
| Eating-Sleeping | 0 1 2 3 4 5 |
| Essential for life | 0 1 2 3 4 5 |
| Other correct answer | 0 1 2 3 4 5 |
| REPEITION | 0 1 2 3 4 5 |
| "I WOULD LIKE TO GO HOME/OUT" | 0 1 2 3 4 5 |
| 1 or 2 missed/wrong words | 0 1 2 3 4 5 |
| "NO IF'S, AND'S, OR BUTS ..." | 0 1 2 3 4 5 |
| READ AND OBEY "CLOSE YOUR EYES" | 0 1 2 3 4 5 |
| Obey without prompting | 0 1 2 3 4 5 |
| Obey after prompting | 0 1 2 3 4 5 |
| Ranks sized only | 0 1 2 3 4 5 |
| (spontaneously or on request) | 0 1 2 3 4 5 |
| WRITING (1 minute) | 0 1 2 3 4 5 |
| (I) WOULD LIKE TO GO HOME/OUT | 0 1 2 3 4 5 |
| (MMS: Spontaneous sentence: 0 1) | 0 1 2 3 4 5 |
| COPYING TWO PENTAGONS (1 minute) | 0 1 2 3 4 5 |
| Each Pentagon | 0 1 2 3 4 5 |
| 5 approximately equal sides | 0 1 2 3 4 5 |
| 5 unequal (2:3:1) sides | 0 1 2 3 4 5 |
| Other enclosed figure | 0 1 2 3 4 5 |
| 2 or more lines | 0 1 2 3 4 5 |
| Intersection | 0 1 2 3 4 5 |
| 4 corners | 0 1 2 3 4 5 |
| Not 4-corner enclosure | 0 1 2 3 4 5 |
| THREE-STAGE COMMAND | 0 1 2 3 4 5 |
| TAKE THIS PAPER WITH YOUR LEFT/RIGHT HAND | 0 1 2 3 4 5 |
| _FOLD IT IN HALF, AND_ | 0 1 2 3 4 5 |
| _HAND IT BACK TO ME_ | 0 1 2 3 4 5 |
| SECOND RECALL | 0 1 2 3 4 5 |
| (Something to wear) | 0 1 2 3 4 5 |
| (Color) | 0 1 2 3 4 5 |
| (Good personal quality) | 0 1 2 3 4 5 |
Patient Health Questionnaire-2 (PHQ-2)

The PHQ-2 enquires about the frequency of depressed mood and anhedonia over the past two weeks. The PHQ-2 includes the first two items of the PHQ-9.

The purpose of the PHQ-2 is to screen for depression in a “first-step” approach.

Patients who screen positive should be further evaluated with the PHQ-9 to determine whether they meet criteria for a depressive disorder.

**Informed consent**

☐ I have understand and wilfully participate in the research by answering the following questions.

| Over the last 2 weeks, how often have you been bothered by the following problems? | Not at all | Several days | More than half the days | Nearly every day |
|---|---|---|---|---|
| 1. Little interest or pleasure in doing things | 0 | + 1 | + 2 | + 3 |
| 2. Feeling down, depressed or hopeless | 0 | + 1 | + 2 | + 3 |

**Total Score**

**Interpretation**

A PHQ-2 score ranges from 0-6. The authors identified a score of 3 as the optimal cut-off point when using the PHQ-2 to screen for depression.

If the score is 3 or greater, major depressive disorder is likely.

Patients who screen positive should be further evaluated with the PHQ-9, other diagnostic instruments, or direct interview to determine whether they meet criteria for a depressive disorder.

Source: Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: Validity of a Two-Item Depression Screener. Medical Care. 2003;41:1284-92.

The above Questionnaire is adapted from https://www.hivatis.org/page/mental-health-screening/phq-2.
Patient Health Questionnaire-9 (PHQ-9)

The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Informed consent

☐ I have understood and willfully participate in the research by answering the following questions.

| Over the last 2 weeks, how often have you been bothered by the following problems? | Not at all | Several days | More than half the days | Nearly every day |
|---|---|---|---|---|
| 1. Little interest or pleasure in doing things | 0 | +1 | +2 | +3 |
| 2. Feeling down, depressed or hopeless | 0 | +1 | +2 | +3 |
| 3. Trouble falling asleep, staying asleep, or sleeping too much | 0 | +1 | +2 | +3 |
| 4. Feeling tired or having little energy | 0 | +1 | +2 | +3 |
| 5. Poor appetite or overeating | 0 | +1 | +2 | +3 |
| 6. Feeling bad about yourself - or that you’re a failure or have let yourself or your family down | 0 | +1 | +2 | +3 |
| 7. Trouble concentrating on things, such as reading the newspaper or watching television | 0 | +1 | +2 | +3 |
| 8. Moving or speaking so slowly that other people could have noticed. Or, the opposite - being so fidgety or restless that you have been moving around a lot more than usual | 0 | +1 | +2 | +3 |
| 9. Thoughts that you would be better off dead or of hurting yourself in some way | 0 | +1 | +2 | +3 |

Total Score

Interpretation

Total scores of 5, 10, 15, and 20 represent cut-off points for mild, moderate, moderately severe and severe depression, respectively.

Question 9 is a single screening question on suicide risk. A patient who answers yes to question 9 needs further assessment for suicide risk by an individual who is competent to assess this risk.

FIGURE 6: Patient Health Questionnaire-9

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, Indira Gandhi Government Medical College, Nagpur issued approval IGGMC/Pharmacology/IEC/68/2016. My proposal has been discussed and approved unanimously by the Institutional Ethics Committee of Indira Gandhi Government Medical College, Nagpur and I was permitted to carry out study. I was advised to follow Schedule ‘Y’, ICH, GCP, CPSEA, and other guidelines as applicable and amended from time to time. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
1. UNAIDS data 2019. (2019). Accessed: December 04, 2019: https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf.
2. Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C: Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol. 2001, 20:146–55.
3. Saylor D, Dickhens AM, Sacktor N, et al.: HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol. 2016, 12:234-48. 10.1038/nrneurol.2016.27
4. Cousensbergh C, Van Der Gaag RJ, Koeter M, De Ruiter C, Van den Brink W: Screening for substance abuse among adolescents validity of the CAGE-AID in youth mental health care. Subst Use Misuse. 2009, 44:823-34. 10.1080/10826080802484264
5. Leonardson CR, Kemper E, Ness FK, Koplin BA, Daniels MC, Leonardson GA: Validity and reliability of the audit and CAGE-AID in Northern Plains American Indians. Psychol Rep. 2005, 97:161-66. 10.2466/pr0.97.1.161-166
6. Becker JT, Kingsley LA, Molsberry S, et al.: Cohort profile: recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. Int J Epidemiol. 2015, 44:1506-16. 10.1093/ije/dyu092
7. Hu X, Zhou Y, Long J, et al.: Diagnostic accuracy of the International HIV Dementia Scale and HIV Dementia Scale: a meta-analysis. Exp Ther Med. 2012, 4:665-8. 10.3892/etm.2012.665
8. Oshinaike OG, Akinbami AA, Ojo OO, Ojini IF, Okubadejo UN, Danesi AM: Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in assessing cognitive function in Nigerian HIV patients on antiretroviral therapy. AIDS Res Treat. 2012, 2012:581531. 10.1155/2012/581531
9. Heaton RK, Clifted DB, Franklin DR Ir, et al.: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010, 75:2087-96. 10.1212/WNL.0b013e318200d727
10. Schouten J, Cinque P, Giatsis M, Reiss P, Portegies P: HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011, 25:561-75. 10.1097/QAD.0b013e328347f179
11. Giatsis M, Price RW, Nilsson S: The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis. 2011, 11:556. 10.1186/1471-2334-11-556
12. Kumar S, Himanshu D, Tandon R, Atam V, Sowlani KK, Verma SK: Prevalence of HIV associated neurocognitive disorder using Modified Mini Mental State Examination and its correlation with CD4 counts and anti-retroviral therapy. J Assoc Physicians India. 2019, 67:47-51.
13. Yusuf AJ, Hassan A, Mamman AI, Muktar HM, Suleiman AM, Baiyewu O: Prevalence of HIV-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in Northern Nigeria. J Int Assoc Provid AIDS Care. 2017, 16:48-55. 10.1177/2329574144558559
14. Njamnshi AK, Bissek AC, Ongolo-Zogo P, et al.: Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon. J Neurol Sci. 2009, 285:149-53. 10.1016/j.jns.2009.06.043